PubRank

Lovastatin: Immunomodulatory Value Evaluation (LIVE)

Clinical Trial ID NCT00721305

PubWeight™ 8.12‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00721305

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998 53.26
2 Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997 18.10
3 Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts. J Virol 2000 6.47
4 Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 2003 5.85
5 International consultation on the criminalization of HIV transmission: 31 October-2 November 2007, Geneva, Switzerland. Joint United Nations Programme on HIV/AIDS (UNAIDS) Geneva, United Nations Development Programme (UNDP), New York, 2007. Reprod Health Matters 2009 5.30
6 Regression analysis for correlated data. Annu Rev Public Health 1993 5.29
7 The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002 5.24
8 ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002 4.50
9 Co-receptors for HIV-1 entry. Curr Opin Immunol 1997 4.31
10 Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. The Los Angeles Center, Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 1993 3.91
11 Membrane raft microdomains mediate lateral assemblies required for HIV-1 infection. EMBO Rep 2000 3.23
12 Involvement of a leukocyte adhesion receptor (LFA-1) in HIV-induced syncytium formation. Science 1989 2.77
13 Lipid rafts and HIV pathogenesis: host membrane cholesterol is required for infection by HIV type 1. AIDS Res Hum Retroviruses 2001 2.60
14 Host-derived ICAM-1 glycoproteins incorporated on human immunodeficiency virus type 1 are biologically active and enhance viral infectivity. J Virol 1997 2.54
15 The Nef protein of HIV-1 associates with rafts and primes T cells for activation. Proc Natl Acad Sci U S A 2000 2.42
16 A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol 2003 2.37
17 Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke 1999 2.12
18 Statins inhibit HIV-1 infection by down-regulating Rho activity. J Exp Med 2004 2.00
19 Binding of human immunodeficiency virus type 1 to immature dendritic cells can occur independently of DC-SIGN and mannose binding C-type lectin receptors via a cholesterol-dependent pathway. J Virol 2003 2.00
20 The acquisition of host-encoded proteins by nascent HIV-1. Immunol Today 1998 1.99
21 A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma. J Immunol 2004 1.88
22 Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev 2004 1.84
23 Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain. J Mol Biol 1999 1.83
24 Raft membrane domains: from a liquid-ordered membrane phase to a site of pathogen attack. Semin Immunol 2001 1.81
25 Role for human immunodeficiency virus type 1 membrane cholesterol in viral internalization. J Virol 2002 1.81
26 Nef increases the synthesis of and transports cholesterol to lipid rafts and HIV-1 progeny virions. Proc Natl Acad Sci U S A 2003 1.69
27 Role of cholesterol in human immunodeficiency virus type 1 envelope protein-mediated fusion with host cells. J Virol 2002 1.64
28 Virion-associated cholesterol is critical for the maintenance of HIV-1 structure and infectivity. AIDS 2002 1.55
29 Secretory IgA specific for a conserved epitope on gp41 envelope glycoprotein inhibits epithelial transcytosis of HIV-1. J Immunol 2001 1.54
30 Formation of virus assembly intermediate complexes in the cytoplasm by wild-type and assembly-defective mutant human immunodeficiency virus type 1 and their association with membranes. J Virol 1999 1.47
31 The role of intranuclear lipids. Biol Cell 2004 1.46
32 Lipid rafts and HIV pathogenesis: virion-associated cholesterol is required for fusion and infection of susceptible cells. AIDS Res Hum Retroviruses 2003 1.43
33 Anti-inflammatory and immunomodulatory effects of statins. Kidney Int 2003 1.39
34 Efficient virus transmission from dendritic cells to CD4+ T cells in response to antigen depends on close contact through adhesion molecules. Virology 1997 1.39
35 Inhibition of hydroxymethylglutaryl-coenzyme a reductase reduces Th1 development and promotes Th2 development. Circ Res 2003 1.38
36 A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. AIDS Res Hum Retroviruses 2005 1.37
37 Human immunodeficiency virus type 1 Gag contains a dileucine-like motif that regulates association with multivesicular bodies. J Virol 2004 1.32
38 Sphingomyelin and cholesterol promote HIV-1 gp41 pretransmembrane sequence surface aggregation and membrane restructuring. J Biol Chem 2002 1.31
39 Blocking of HIV-1 infection by targeting CD4 to nonraft membrane domains. J Exp Med 2002 1.28
40 LFA-1 expression on target cells promotes human immunodeficiency virus type 1 infection and transmission. J Virol 2001 1.26
41 Lovastatin inhibits HIV-1 expression in H9 human T lymphocytes cultured in cholesterol-poor medium. Biomed Pharmacother 1994 1.23
42 Identification of a conserved domain of the HIV-1 transmembrane protein gp41 which interacts with cholesteryl groups. Biochim Biophys Acta 2002 1.22
43 Mechanisms of immune activation of human immunodeficiency virus in monocytes/macrophages. J Virol 1993 1.22
44 Statin-induced immunomodulatory effects on human T cells in vivo. Atherosclerosis 2004 1.19
45 Studies of adhesion of lymphocytic cells: implications for sexual transmission of human immunodeficiency virus. Biol Reprod 1993 1.18
46 Statin compounds reduce human immunodeficiency virus type 1 replication by preventing the interaction between virion-associated host intercellular adhesion molecule 1 and its natural cell surface ligand LFA-1. J Virol 2004 1.15
47 Cholesterol is essential for mitosis progression and its deficiency induces polyploid cell formation. Exp Cell Res 2004 1.14
48 HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis. Atherosclerosis 2004 1.13
49 Increased infectivity of HIV type 1 particles bound to cell surface and solid-phase ICAM-1 and VCAM-1 through acquired adhesion molecules LFA-1 and VLA-4. AIDS Res Hum Retroviruses 2000 1.12
50 Evaluation of the anti-HIV activity of statins. AIDS 2005 1.07
51 Inhibition of lymphocyte endothelial adhesion and in vivo lymphocyte migration to cutaneous inflammation by TA-3, a new monoclonal antibody to rat LFA-1. J Immunol 1992 1.04
52 Inhibition of chemokine receptor function by membrane cholesterol oxidation. Exp Cell Res 2003 1.04
53 The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells. Swiss Med Wkly 2001 1.02
54 Human follicular dendritic cells remain uninfected and capture human immunodeficiency virus type 1 through CD54-CD11a interaction. J Virol 1999 1.01
55 Intercellular adhesion molecules (ICAM)-1 ICAM-2 and ICAM-3 function as counter-receptors for lymphocyte function-associated molecule 1 in human immunodeficiency virus-mediated syncytia formation. Eur J Immunol 1994 0.98
56 Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART. AIDS 2003 0.98
57 Safety and efficacy of HMG-CoA reductase inhibitors for treatment of hyperlipidemia in patients with HIV infection. Pharmacotherapy 2000 0.92
58 HMG-CoA reductase inhibitors. Adv Protein Chem 2001 0.90
59 Pravastatin does not have a consistent antiviral effect in chronically HIV-infected individuals on antiretroviral therapy. AIDS 2005 0.90
60 Lipid lowering therapy with fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy: comparison of efficacy and interaction with indinavir. Infection 2004 0.88
61 Fibrates or statins and lipid plasma levels in 245 patients treated with highly active antiretroviral therapy. Aquitaine Cohort, France, 1999-2001. HIV Med 2004 0.87
62 Early intervention with atorvastatin modulates TH1/TH2 imbalance in patients with acute coronary syndrome: from bedside to bench. Circulation 2004 0.86
63 The effect of statins on HIV rebound and blips. J Acquir Immune Defic Syndr 2005 0.85
64 HMG-CoA reductase inhibitors as immunomodulators: potential use in transplant rejection. Drugs 2002 0.83
65 Antiretroviral effect of lovastatin on HIV-1-infected individuals without highly active antiretroviral therapy (The LIVE study): a phase-II randomized clinical trial. Trials 2009 0.82
66 Expression of adhesion molecules and CD28 on T lymphocytes during human immunodeficiency virus infection. Clin Diagn Lab Immunol 1998 0.81
67 Human immunodeficiency virus pathogenesis and prospects for immune control in patients with established infection. Clin Infect Dis 2001 0.80
68 Long-term statin use does not act on the temporal trend of CD4 cell count in patients on virologically effective HAART. AIDS 2006 0.80
69 Prescribing of contraindicated protease inhibitor and statin combinations among HIV-infected persons. J Acquir Immune Defic Syndr 2005 0.80
70 Ligation of leukocyte function-associated (LFA) molecule-1 provides an accessory signal for T-cell activation with pokeweed mitogen. Scand J Immunol 1994 0.79
71 Alterations in cholesterol metabolism restrict HIV-1 trans infection in nonprogressors. MBio 2014 0.79
72 Randomized clinical trial of lovastatin in HIV-infected, HAART naïve patients (NCT00721305). J Infect 2012 0.78
73 Safety and efficacy of low dose simvastatin in cardiac transplant recipients treated with cyclosporine. Transplantation 1994 0.78
74 Pleiotropic effects of statins: moving beyond cholesterol control. Curr Atheroscler Rep 2005 0.76
75 In vivo effect of statins on the expression of the HIV co-receptors CCR5 and CXCR4. AIDS Res Ther 2013 0.75
Next 100